These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38856778)

  • 1. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials.
    Tungjitviboonkun S; Bumrungratanayos N; Jitwimungsanon J; Kheamakulvanich T; Siramongkholkarn S
    Ann Hematol; 2024 Sep; 103(9):3357-3368. PubMed ID: 38856778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
    González-López TJ; Bermejo-Vega N; Cardesa-Cabrera R; Martínez-Robles V; Aguilar-Monserrate G; Pérez-Segura G; Domingo A; Luis-Navarro J; Lakhwani S; Acedo N; Lozano ML; Bernat S; Torres-Tienza A; Ruano A; Jarque I; Galán P; Benet C; Marcellini S; Jimenez-Bárcenas R; Martínez-Carballeira D; De Miguel-Llorente D; Perona-Blázquez A; Gonzalez-Gascón I; Lopez-Ansoar E; Alonso-Alonso JM; Bengochea-Casado ML; Díaz-Gálvez FJ; Moretó A; Moreno-Jiménez G; Hernández-Martin R; de Cabo E; Dávila-Valls J; Cuesta A; Pastoriza C; Hermida-Fernández GJ; García C; Pozas-Mañas MA; Aguilar C; Fernandez-Jimenez D; Navas-Elorza B; López-Santamaría Castro C; Lorenzo A; Ortín X; García M; Piernas S; Díaz-Santa J; Soto I; Provan D; García-Donas Gabaldón G
    Blood; 2024 Aug; 144(6):646-656. PubMed ID: 38843478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
    Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
    Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
    Paik J
    Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
    Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
    Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fostamatinib or Thrombopoietin for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost.
    Dranitsaris G; Peevyhouse A; Wood T; Kreychman Y; Neuhalfen H; Moezi M
    Acta Haematol; 2024; 147(3):333-343. PubMed ID: 37778326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fostamatinib for the treatment of immune thrombocytopenia in adults.
    Moore DC; Gebru T; Muslimani A
    Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world clinical outcomes with fostamatinib for the treatment of refractory chronic immune thrombocytopenia: a single-center experience.
    Moore DC; Elmes JB; Arnall JR; Pineda-Roman M
    Blood Coagul Fibrinolysis; 2024 Sep; 35(6):316-320. PubMed ID: 39012641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
    Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
    Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
    Bussel JB; Arnold DM; Boxer MA; Cooper N; Mayer J; Zayed H; Tong S; Duliege AM
    Am J Hematol; 2019 May; 94(5):546-553. PubMed ID: 30784097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
    Dierickx D; Neefs J
    Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
    Mehta AR; Kefela A; Toste C; Sweet D
    Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
    Newland A; McDonald V
    Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia.
    Mingot-Castellano ME; Bastida JM; Ghanima W; Ruiz Sainz E; Nuñez Vazquez R; Pedrote Amador B; Abdel-Kader Martín L; Piquer-Monsonis D; Canaro M
    Br J Haematol; 2024 Oct; 205(4):1551-1555. PubMed ID: 38895923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fostamatinib: First Global Approval.
    Markham A
    Drugs; 2018 Jun; 78(9):959-963. PubMed ID: 29869203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
    Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB;
    Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.
    Niscola P; Scaramucci L; Giovannini M
    Immunotherapy; 2018 Jan; 10(1):5-7. PubMed ID: 29192558
    [No Abstract]   [Full Text] [Related]  

  • 18. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
    Bajpai M
    IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fostamatinib for persistent/chronic adult immune thrombocytopenia.
    Newland A; Lee EJ; McDonald V; Bussel JB
    Immunotherapy; 2018 Jan; 10(1):9-25. PubMed ID: 28967793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
    Lee EJ; Izak M; Bussel JB
    Br J Haematol; 2020 Apr; 189(2):379-382. PubMed ID: 31900937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.